According to a recent LinkedIn post from Neuromod Devices Ltd, the company participated in the Australian College of Audiology incorporating HAASA’s ACAud 2026 event, engaging attendees from Booth 31. The post highlights its Lenire device as a “groundbreaking tinnitus treatment,” supported by three large-scale clinical trials and real‑world patient data.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post cites statistics from The Medical Journal of Australia indicating that 33% of Australians have experienced tinnitus, with 17% reporting constant noise, underscoring a sizable addressable market. For investors, the emphasis on clinical validation, professional‑channel outreach to audiologists and ENTs, and growing awareness in the Australian market may signal ongoing commercial ramp‑up efforts and potential revenue expansion for Neuromod Devices in tinnitus care.